One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post-Earnings
2026-02-26 17:00:27 ET
On February 18, 2026, Front Street Capital Management, Inc. reported a buy of 156,069 shares of Enovis (NYSE:ENOV) , an estimated $4.61 million trade based on quarterly average pricing.
According to a filing with the Securities and Exchange Commission dated February 18, 2026, Front Street Capital Management, Inc. increased its position in Enovis (NYSE:ENOV) by 156,069 shares during the fourth quarter. The estimated transaction value was $4.61 million, calculated using the average unadjusted closing price for the period. The quarter-end value of the Enovis position rose by $3.40 million, reflecting both the additional shares and share price changes.
Enovis operates as a global medical technology company with a focus on musculoskeletal health. The company leverages a broad product portfolio and established distribution channels to serve a diverse base of healthcare professionals and institutions. Its scale and specialized offerings position it to address a wide range of patient needs in orthopedic care and rehabilitation.
NASDAQ: ENOV
ENOV Trading
0.78% G/L:
$24.41 Last:
458,617 Volume:
$24.28 Open:
